The role of membrane technology in palm oil mill effluent (POME) decontamination: Current trends and future prospects.

This article reviews the role of membrane systems in treating palm oil mill effluent (POME), a waste generated by the palm industry. The review focuses on various membrane systems such as microfiltration (MF), ultrafiltration (UF), nanofiltration (NF), and reverse osmosis (RO), highlighting their effectiveness in removing pollutants and recovering water. Special attention is given to hybrid systems integrating membrane bioreactors (MBRs) and other advanced processes to enhance fouling control, improve water quality, and promote sustainability.

Efficacy of Angiotensin Receptor Neprilysin Inhibitor (ARNI) in right ventricular systolic dysfunction and preserved LV ejection fraction: A randomized clinical trial.

Angiotensin Receptor Neprilysin Inhibitor (ARNI) has not shown to be promising in Heart failure with preserved LVEF. Role of ARNI in Right ventricular systolic dysfunction with preserved LVEF needs to be evaluated. We took 50 patients with isolated RV systolic dysfunction and divided them into two groups of 25 patients each- Conventional treatment and ARNI in addition to conventional treatment.

Aliphatic substrates-mediated unique rapid room temperature synthesis of carbon quantum dots for fenofibrate versatile analysis.

Background: The current synthetic strategies for carbon dots (CDs) are usually time-consuming, rely on complicated processes, and need high temperatures and energy. Recent studies have successfully synthesized CDs at room temperature. Unfortunately, most CDs synthesized at room temperature are obtained under harsh reaction conditions, prepared using aromatic precursors, or need a long time to generate.

Early vs Late Anticoagulation After Ischemic Stroke in Patients With Atrial Fibrillation and Covert Brain Infarcts.

Background And Objectives: Covert brain infarcts (CBIs) in patients with first-ever ischemic stroke (IS) and atrial fibrillation (AF) are associated with an increased risk of stroke recurrence. We aimed to assess whether CBIs modify the treatment effect of early vs late initiation of direct oral anticoagulants (DOACs) in patients with IS and AF.

Methods: We conducted a post hoc analysis of the international, multicenter, randomized-controlled ELAN trial, which compared early (<48 hours after ischemic stroke for minor and moderate stroke, 6-7 days for major stroke) vs late (>48 hours for minor, 3-4 days for moderate, 12-14 days for major stroke) initiation of DOACs in patients with IS and AF.

Sequelae of B-Cell Depleting Therapy: An Immunologist's Perspective.

B-cell depleting therapy (BCDT) has revolutionised the treatment of B-cell malignancies and autoimmune diseases by targeting specific B-cell surface antigens, receptors, ligands, and signalling pathways. This narrative review explores the mechanisms, applications, and complications of BCDT, focusing on the therapeutic advancements since the introduction of rituximab in 1997. Various monoclonal antibodies and kinase inhibitors are examined for their roles in depleting B cells through antibody-dependent and independent mechanisms.